JP2005535588A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005535588A5 JP2005535588A5 JP2004501452A JP2004501452A JP2005535588A5 JP 2005535588 A5 JP2005535588 A5 JP 2005535588A5 JP 2004501452 A JP2004501452 A JP 2004501452A JP 2004501452 A JP2004501452 A JP 2004501452A JP 2005535588 A5 JP2005535588 A5 JP 2005535588A5
- Authority
- JP
- Japan
- Prior art keywords
- factor viii
- amino acid
- acid sequence
- seq
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108010054218 Factor VIII Proteins 0.000 claims 37
- 102000001690 Factor VIII Human genes 0.000 claims 37
- 229960000301 factor viii Drugs 0.000 claims 34
- 125000003275 alpha amino acid group Chemical group 0.000 claims 23
- 238000000034 method Methods 0.000 claims 16
- 239000013060 biological fluid Substances 0.000 claims 12
- 108090000765 processed proteins & peptides Proteins 0.000 claims 11
- 239000000203 mixture Substances 0.000 claims 10
- 230000000694 effects Effects 0.000 claims 8
- 239000008194 pharmaceutical composition Substances 0.000 claims 8
- 230000015556 catabolic process Effects 0.000 claims 6
- 238000006731 degradation reaction Methods 0.000 claims 6
- 230000003993 interaction Effects 0.000 claims 6
- 230000004064 dysfunction Effects 0.000 claims 3
- 230000002401 inhibitory effect Effects 0.000 claims 3
- 229940029329 intrinsic factor Drugs 0.000 claims 3
- 102100026735 Coagulation factor VIII Human genes 0.000 claims 2
- 201000003542 Factor VIII deficiency Diseases 0.000 claims 2
- 208000009292 Hemophilia A Diseases 0.000 claims 2
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 claims 2
- 208000027276 Von Willebrand disease Diseases 0.000 claims 2
- 239000003146 anticoagulant agent Substances 0.000 claims 2
- 208000015294 blood coagulation disease Diseases 0.000 claims 2
- 239000003527 fibrinolytic agent Substances 0.000 claims 2
- 230000003480 fibrinolytic effect Effects 0.000 claims 2
- 230000005764 inhibitory process Effects 0.000 claims 2
- 238000001356 surgical procedure Methods 0.000 claims 2
- 230000002537 thrombolytic effect Effects 0.000 claims 2
- 208000012137 von Willebrand disease (hereditary or acquired) Diseases 0.000 claims 2
- 150000001413 amino acids Chemical class 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 239000003381 stabilizer Substances 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US37635102P | 2002-04-29 | 2002-04-29 | |
| PCT/EP2003/004425 WO2003093313A2 (en) | 2002-04-29 | 2003-04-28 | Antagonists of factor viii interaction with low-density lipoprotein receptor-related protein |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010130425A Division JP2010202664A (ja) | 2002-04-29 | 2010-06-07 | 第ｖｉｉｉ因子と低密度リポタンパク質レセプター関連タンパク質との相互作用のアンタゴニスト |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005535588A JP2005535588A (ja) | 2005-11-24 |
| JP2005535588A5 true JP2005535588A5 (OSRAM) | 2006-07-06 |
Family
ID=29401334
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004501452A Pending JP2005535588A (ja) | 2002-04-29 | 2003-04-28 | 第ｖｉｉｉ因子と低密度リポタンパク質レセプター関連タンパク質との相互作用のアンタゴニスト |
| JP2010130425A Pending JP2010202664A (ja) | 2002-04-29 | 2010-06-07 | 第ｖｉｉｉ因子と低密度リポタンパク質レセプター関連タンパク質との相互作用のアンタゴニスト |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010130425A Pending JP2010202664A (ja) | 2002-04-29 | 2010-06-07 | 第ｖｉｉｉ因子と低密度リポタンパク質レセプター関連タンパク質との相互作用のアンタゴニスト |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US8586538B2 (OSRAM) |
| EP (1) | EP1497330B1 (OSRAM) |
| JP (2) | JP2005535588A (OSRAM) |
| AT (1) | ATE463514T1 (OSRAM) |
| AU (1) | AU2003227687B2 (OSRAM) |
| CA (1) | CA2484155C (OSRAM) |
| DE (1) | DE60332011D1 (OSRAM) |
| DK (1) | DK1497330T3 (OSRAM) |
| ES (1) | ES2343681T3 (OSRAM) |
| WO (1) | WO2003093313A2 (OSRAM) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1539235A2 (en) | 2002-07-01 | 2005-06-15 | Human Genome Sciences, Inc. | Antibodies that specifically bind to reg iv |
| EP1454632A1 (en) * | 2003-02-07 | 2004-09-08 | Aventis Behring GmbH, Intellectual Property/Legal | Pharmaceutical preparation for the treatment of blood-clotting disorders containing factor VIII derived peptides |
| AR045563A1 (es) | 2003-09-10 | 2005-11-02 | Warner Lambert Co | Anticuerpos dirigidos a m-csf |
| WO2006003183A1 (de) * | 2004-07-02 | 2006-01-12 | Alois Jungbauer | Peptide zur blockierung von fviii-inhibitoren |
| EP1816201A1 (en) | 2006-02-06 | 2007-08-08 | CSL Behring GmbH | Modified coagulation factor VIIa with extended half-life |
| JP2009274958A (ja) | 2006-08-31 | 2009-11-26 | Nara Prefecture | 血液凝固第ｖｉｉｉ因子の活性化を促進する抗体 |
| JP5448839B2 (ja) | 2006-12-22 | 2014-03-19 | ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー | インビボで長い半減期を有する修飾された凝固因子 |
| KR20110017420A (ko) * | 2008-06-04 | 2011-02-21 | 바이엘 헬스케어 엘엘씨 | 폰 빌레브란트 질환의 치료를 위한 ｆｖｉｉｉ 뮤테인 |
| ES2531464T3 (es) | 2008-06-24 | 2015-03-16 | Csl Behring Gmbh | Factor VIII, factor de von Willebrand o sus complejos con semivida in vivo prolongada |
| JP5394864B2 (ja) * | 2009-09-10 | 2014-01-22 | アスモ株式会社 | モータ |
| WO2011095604A1 (en) * | 2010-02-04 | 2011-08-11 | Octapharma Biopharmaceuticals Gmbh | Half-life prolongation of proteins |
| CN103209992A (zh) | 2010-09-15 | 2013-07-17 | 诺沃—诺迪斯克有限公司 | 具有减少的细胞摄取的因子viii变体 |
| ES2651523T3 (es) | 2012-02-15 | 2018-01-26 | Csl Behring Gmbh | Variantes del Factor de von Willebrand que tienen afinidad de unión al Factor VIII mejorada |
| ES2657291T3 (es) | 2013-04-22 | 2018-03-02 | Csl Ltd. | Un complejo covalente de factor de von Willebrand y factor VIII asociado por un puente disulfuro |
| WO2016000039A1 (en) | 2014-07-02 | 2016-01-07 | Csl Limited | Modified von willebrand factor |
| DK3265483T3 (da) | 2015-03-06 | 2020-03-02 | CSL Behring Lengnau AG | Modificeret von Willebrand-faktor med forbedret halveringstid |
| EP3297656B1 (en) | 2015-05-22 | 2020-01-08 | CSL Behring Lengnau AG | Truncated von willebrand factor polypeptides for treating hemophilia |
| EP4089109A3 (en) | 2015-05-22 | 2023-03-01 | CSL Behring Lengnau AG | Methods for preparing modified von willebrand factor |
| KR20180094114A (ko) | 2016-01-07 | 2018-08-22 | 체에스엘 베링 리컴비넌트 퍼실리티 아게 | 돌연변이된 절단된 폰 빌레브란트 인자 |
| WO2017117630A1 (en) | 2016-01-07 | 2017-07-13 | Csl Limited | Mutated von willebrand factor |
| TW201828975A (zh) | 2016-11-11 | 2018-08-16 | 瑞士商Ｃｓｌ貝林重組技能公司 | 用於治療血友病之截短型類血友病因子（ｖｏｎ Ｗｉｌｌｅｂｒａｎｄ ｆａｃｔｏｒ）多肽類 |
| AU2017358865A1 (en) | 2016-11-11 | 2019-05-09 | CSL Behring Lengnau AG | Truncated von willebrand factor polypeptides for extravascular administration in the treatment or prophylaxis of a blood coagulation disorder |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE205506T1 (de) * | 1995-06-12 | 2001-09-15 | Sanquin Bloedvoorziening | Faktor ix bindende peptide abgeleitet von faktor vii und ihre verwendung als inhibitoren der blutgerinnung |
| JP2002514422A (ja) * | 1998-05-08 | 2002-05-21 | ステイヒテイング・サンキン・ブロードボールジーニング | インヒビターを有する血友病ａ患者の診断および治療方法 |
| DE59914490D1 (de) * | 1998-11-10 | 2007-10-18 | Sanquin Bloedvoorziening | Ein faktor viii-polypeptid mit faktor viii:c-aktivität |
| AT409335B (de) * | 1998-11-10 | 2002-07-25 | Immuno Ag | Pharmazeutisches präparat enthaltend einen rezeptor-antagonisten zur behandlung von blutgerinnungsstörungen |
-
2003
- 2003-04-28 JP JP2004501452A patent/JP2005535588A/ja active Pending
- 2003-04-28 DE DE60332011T patent/DE60332011D1/de not_active Expired - Lifetime
- 2003-04-28 AU AU2003227687A patent/AU2003227687B2/en not_active Ceased
- 2003-04-28 US US10/512,907 patent/US8586538B2/en not_active Expired - Fee Related
- 2003-04-28 WO PCT/EP2003/004425 patent/WO2003093313A2/en not_active Ceased
- 2003-04-28 DK DK03725109.7T patent/DK1497330T3/da active
- 2003-04-28 AT AT03725109T patent/ATE463514T1/de active
- 2003-04-28 EP EP03725109A patent/EP1497330B1/en not_active Expired - Lifetime
- 2003-04-28 CA CA2484155A patent/CA2484155C/en not_active Expired - Lifetime
- 2003-04-28 ES ES03725109T patent/ES2343681T3/es not_active Expired - Lifetime
-
2010
- 2010-06-07 JP JP2010130425A patent/JP2010202664A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005535588A5 (OSRAM) | ||
| Seifert et al. | Recurrence phenomena after immunoglobulin therapy for snake envenomations: Part 1. Pharmacokinetics and pharmacodynamics of immunoglobulin antivenoms and related antibodies | |
| JP6356106B2 (ja) | 凍結乾燥された治療用ペプチボディ製剤 | |
| JP4175668B2 (ja) | Ｏｂ融合タンパク質組成物および方法 | |
| US20170246372A1 (en) | Systems, compositions, and methods for transplantation and treating conditions | |
| JP2010202664A5 (OSRAM) | ||
| EP2124548B1 (en) | Disintegrin variants and pharmaceutical uses thereof | |
| Machold et al. | Adalimumab–a new TNF-α antibody for treatment of inflammatory joint disease | |
| JP2012523438A5 (OSRAM) | ||
| JP2005506345A5 (OSRAM) | ||
| JP2009537563A5 (OSRAM) | ||
| US11993640B2 (en) | Treating inflammatory lung disease | |
| JP2008521426A5 (OSRAM) | ||
| US20240335507A1 (en) | Therapeutic composition for use in the treatment of covid-19 and other cytokine storm associated disorders | |
| CA2233138A1 (en) | Inhibitors of integrin receptors and their therapeutical uses | |
| Frank | Hereditary angiodema: a current state-of-the-art review, VI: novel therapies for hereditary angioedema | |
| JP2010512349A (ja) | 低出血性抗凝固性融合タンパク質の調製および使用 | |
| JP2002507886A (ja) | アンギオテンシン誘導体 | |
| AU2017305856B2 (en) | Pharmaceutical formulations of C1 esterase inhibitor | |
| AU2016221627A1 (en) | Pharmaceutical formulations of C1 esterase inhibitor | |
| EP0333517A2 (en) | Method and agent for inhibiting the binding of human polymorphonuclear leukocytes to endothelium and compositions therefor | |
| RU2649760C1 (ru) | Способ лечения острого инфаркта миокарда с подъемом сегмента ST, осложненного кардиогенным шоком | |
| JP5836968B2 (ja) | ＩｇＥ媒介性疾患の処置方法 | |
| JP2022066353A (ja) | 膵炎および疼痛をデス受容体アゴニストで処置するための組成物および方法 | |
| JP2017513831A5 (OSRAM) |